Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics

Inhibitors of cyclin-dependent kinases as cancer therapeutics

(2017) Steven R. Whittaker et al.   PHARMACOLOGY & THERAPEUTICS

BRAFmutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions

(2016) Ann-Cathrine Larsen et al.   ACTA OPHTHALMOLOGICA

Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing

(2016) Beryl Royer-Bertrand et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Metastatic disease from uveal melanoma: treatment options and future prospects

(2016) Richard D Carvajal et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth

(2016) Ruzica Bago et al.   EMBO JOURNAL

Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives

(2016) Kimberly M Komatsubara et al.   Future Oncology

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

(2016) J. Van den Bossche et al.   MEDICINAL RESEARCH REVIEWS

Molecular profiling of single circulating tumor cells from lung cancer patients

(2016) Seung-min Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

(2016) Guillaume Carita et al.   Oncotarget

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1

(2016) Zhenfeng Zhang et al.   Theranostics

Management of Primary Acquired Melanosis, Nevus, and Conjunctival Melanoma

(2016) Andrew Kao et al.   Cancer Control

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

(2016) Alison M. Kurimchak et al.   Cell Reports

Driver Mutations in Uveal Melanoma

(2016) Christina L. Decatur et al.   JAMA Ophthalmology

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720

(2015) Aline I Riechardt et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation

(2015) Tetsuo Mashima et al.   CANCER SCIENCE

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer

(2015) R. Ferrarotto et al.   CLINICAL CANCER RESEARCH

BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population

(2015) Ismail Yilmaz et al.   Indian Journal of Pathology and Microbiology

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

(2015) Grazia Ambrosini et al.   Oncotarget

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells

(2015) Emma K Baker et al.   Scientific Reports

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

(2015) Nancy E. Thomas et al.   JAMA Oncology

Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP

(2014) Fa-Xing Yu et al.   CANCER CELL

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

(2014) Xiaodong Feng et al.   CANCER CELL

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

(2014) Richard D. Carvajal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

(2014) B T Gjertsen et al.   LEUKEMIA

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

AnimalTFDB 2.0: a resource for expression, prediction and functional study of animal transcription factors

(2014) Hong-Mei Zhang et al.   NUCLEIC ACIDS RESEARCH

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity

(2013) Adriana Amaro et al.   EUROPEAN JOURNAL OF CANCER

Master regulators of FGFR2 signalling and breast cancer risk

(2013) Michael N. C. Fletcher et al.   Nature Communications

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

(2012) C. J. Ott et al.   BLOOD

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Small-Molecule Inhibition of BRDT for Male Contraception

(2012) Martin M. Matzuk et al.   CELL

The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding Mechanism

(2012) X. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

Genetic and molecular characterization of uveal melanoma cell lines

(2012) K. G. Griewank et al.   Pigment Cell & Melanoma Research

Role of MicroRNA-182 in Posterior Uveal Melanoma: Regulation of Tumor Development through MITF, BCL2 and Cyclin D2

(2012) Dongsheng Yan et al.   PLoS One

FoxM1: A Master Regulator of Tumor Metastasis

(2011) P. Raychaudhuri et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

A Comparative Transcriptomic Analysis of Uveal Melanoma and Normal Uveal Melanocyte

(2011) Jianhong An et al.   PLoS One

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Estimating prognosis for survival after treatment of choroidal melanoma

(2011) Bertil Damato et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1

(2010) Mónica Alvarez-Fernández et al.   EMBO REPORTS

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks

(2009) Paul J. Scutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Aurora B Expression by the Bromodomain Protein Brd4

(2009) J. You et al.   MOLECULAR AND CELLULAR BIOLOGY

Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription

(2009) Anup Dey et al.   MOLECULAR BIOLOGY OF THE CELL

Anaphase-Promoting Complex/Cyclosome-Cdh1-Mediated Proteolysis of the Forkhead Box M1 Transcription Factor Is Critical for Regulated Entry into S Phase

(2008) H. J. Park et al.   MOLECULAR AND CELLULAR BIOLOGY

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE

What is principal component analysis?

(2008) Markus Ringnér   NATURE BIOTECHNOLOGY

Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression

(2008) Zheng Fu et al.   NATURE CELL BIOLOGY